Linezolid oxide

Drug Profile

Linezolid oxide

Alternative Names: PNU 141535

Latest Information Update: 26 May 2003

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pharmacia Corporation
  • Class Antibacterials; Oxazolidinones; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Gram-positive infections

Most Recent Events

  • 26 May 2003 Discontinued - Preclinical for Gram-positive infections in USA (unspecified route)
  • 10 Dec 2001 No-Development-Reported for Gram-positive infections in USA (Unknown route)
  • 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top